Mark Fineman

Dr. Fineman is a seasoned pharmaceutical executive with over thirty years of experience leading R&D for both public and private companies. In these roles, he has led the strategy and execution of multiple programs ranging from early discovery through global commercialization of first-in-class products. Previously, Dr. Fineman was the CSO of Elcelyx Therapeutics where he led all development efforts. Earlier in his career, he held several leadership positions during his lengthy tenure at Amylin Pharmaceuticals, including the Core Team Leadership for Byetta®, the first GLP-1 agonist for the treatment of type 2 diabetes. Dr. Fineman has authored over 50 original publications and is an inventor on more than 15 issued U.S. patents.

Dr. Fineman received a Ph.D. in Medicine at Vrije Universiteit Amsterdam, M.S. and M.A.S. in Molecular Pathology and Clinical Research from the University of California, San Diego, and a B.S. in Microbiology with emphasis in Clinical Chemistry from California Polytechnic State University, San Luis Obispo.